GEOVAX LABS INC (GOVX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.16-5.95%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · GOVX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -89.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
GOVX — director transition
Dated 2026-10-27
Director: The mass resignation of five directors and their replacement by lender-designated nominees indicates a loss of board control due to debt covenants, which is a significant negative signal rather than a routine executive departure.
Why it matters: Nasdaq sent a delisting notice after the share price fell below its $1 minimum. A clear listing outcome would show whether this risk remains active.
Watch forNasdaq confirms that GOVX meets its listing rules or that its appeal or transfer keeps the shares listed.
Also watch forNasdaq confirms delisting or the shares move to a market with lower listing rules.
Why it matters: The study will compare immune responses in about 500 people. Meeting its goal would support the planned approval path.
Supportive ifThe company reports that the study met its goal compared with the approved MVA vaccine.
Worry ifThe company reports that the study missed its goal, or that poor data leave the result unclear.
Why it matters: GeoVax had $3.1 million in cash at June 30 and reported a new loan of up to $1 million. New cash needs or loan use matter as it funds trials.
Worry ifThe November 12 report shows cash below $3.1 million and says the company drew on the loan or needs more funding to keep trials on track.
Less concerning ifThe report shows cash at or above $3.1 million, no loan draw, and no stated need for added funding to keep trials on track.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$388 on $10,000 · ±3.9% | How much price usually moves either way. |
| Bad day | $1,296 loss on $10,000 · 13.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,883 loss on $10,000 · 98.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.